CanSino Biologics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CanSino Biologics Inc.
The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.
Beijing expands mass testing to more areas and Shanghai’s case fatally rate raises questions amid China deals with the worst outbreak in two years.
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
The largest-ever COVID-related lockdown in Shanghai is offering an indication of the effectiveness of current Chinese policies around current controls and domestic vaccines, as well as prompting consideration of future directions for control and treatment measures as the pandemic moves to the endemic phase.
- Other Names / Subsidiaries
- Tianjin CanSino Biotechnology
- CanSino (Shanghai) Biotechnology Co., Ltd